. 2016 Oct 20;11(10):e0164972. doi: 10.1371/journal.pone.0164972

Table 3. Overview of drugs for which CPIC or DPWG guidelines were available at the time of our analysis (mid-2014).

Drugs and substances that we assigned to the ‘core list’ are listed separately. Only ‘core list’ substances were used for generating prescription statistics. Drug substances that were included in the estimation of the number of high-risk drug-phenotype co-occurrences are printed in bold.

Gene	Substances associated with gene in pharmacogenomic guidelines
Core list
CYP2C19	amitriptyline^a^,^b, clomipramine^a^,^b, clopidogrel^a^,^b, desipramine^a, doxepin^b, imipramine^a^,^b, nortriptyline^a^,^b, trimipramine^a, citalopram^b, escitalopram^b, esomeprazole^b, lansoprazole^b, moclobemide^b, omeprazole^b, pantoprazole^b, rabeprazole^b, sertraline^b, voriconazole^b
CYP2C9	warfarin^a, acenocoumarol^b, glibenclamide^b, gliclazide^b, glimepiride^b, phenprocoumon^b, phenytoin^b, tolbutamide^b
CYP2D6	amitriptyline^a^,^b, clomipramine^a^,^b, codeine^a^,^b, desipramine^a, doxepin^a^,^b, imipramine^a^,^b, nortriptyline^a^,^b, trimipramine^a, aripiprazole^b, atomoxetine ^b, carvedilol ^b, clozapine^b, duloxetine^b, flecainide^b, flupenthixol^b, haloperidol^b, metoprolol^b, mirtazapine^b, olanzapine^b, oxycodone^b, paroxetine^b, propafenone^b, risperidone^b, tamoxifen^b, tramadol^b, venlafaxine^b, zuclopenthixol^b
CYP3A5	tacrolimus^b
DPYD	capecitabine^a^,^b, fluorouracil^a^,^b, tegafur^a^,b
TPMT	azathioprine^a^,^b, mercaptopurine^a^,^b, thioguanine^a^,^b
UGT1A1	irinotecan^b
SLCO1B1	simvastatin^a
VKORC1	warfarin^a, phenprocoumon^b
Others (not included in drug prescription statistics)
F5	estrogen-containing oral contraceptives^b
HLA-B	abacavir^a^,^b, allopurinol^a, carbamazepine^a, ribavirin^a^,^b
IFNL3	peginterferon alfa-2a^a, peginterferon alfa-2b^a, ribavirin^a^,^b

a: substance covered by CPIC guideline

b: substance covered by DPWG guideline. CPIC: Clinical Pharmacogenetics Implementation Consortium. DPWG: Dutch Pharmacogenetics Working Group.